ArticleScientific reports2026
Antibacterial and antibiofilm activity of a triterpenoid-rich Eucalyptus globulus leaf extract against gram-positive bacteria.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of an Herbal Formulation Ethanolic Extract onPathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eucalyptus globulus leaf extract (EGL) is a phytocomplex associated with antimicrobial and anti-inflammatory effects, but a comprehensive characterization of its chemical composition and its relationship with biological activity remains limited. In this study, we combined untargeted metabolomic profiling with functional antibacterial and antibiofilm assays to characterize EGL and to investigate the relationship between its chemical composition and biological activity. Untargeted UHPLC-TWIMS-QTOF analysis revealed a complex profile dominated by polyphenols and pentacyclic triterpenoids. Targeted quantification identified asiatic acid and ursolic acid as major triterpenoid components, present at concentrations of 47.29 ± 0.13 µg/mL and 16.12 ± 0.32 µg/mL, respectively. The antibacterial and antibiofilm activities of EGL were evaluated against clinically relevant Gram-positive pathogens, including Streptococcus pyogenes, Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus mutans. The two major triterpenoids identified in the extract, asiatic acid and ursolic acid, were tested separately as reference compounds to explore their individual antibacterial and antibiofilm activity in comparison with the whole extract. EGL inhibited bacterial growth with MIC values ranging from 62.5 µg/mL to 437.5 µg/mL, while the triterpenoids showed stronger activity, with MIC values of 2 µg/mL for ursolic acid and 4 µg/mL for asiatic acid against Streptococcus pyogenes. In antibiofilm assays, asiatic acid and ursolic acid showed MBIC values between 2 and 32 µg/mL, whereas the whole extract displayed partial inhibitory activity. Pre-exposure of bacterial cultures to EGL or its major triterpenoids enhanced antibiofilm efficacy, reducing MBIC values by up to fourfold. Overall, these results indicate that EGL is a chemically characterized multicomponent system with measurable antibacterial and antibiofilm activity against Gram-positive pathogens. The study highlights the importance of integrating chemical profiling with functional assays to better understand the activity of complex phytocomplexes and supports further investigation of phytochemical-based strategies targeting early stages of biofilm formation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.